| Title |
Human recombinant soluble ACE2 (hrsACE2) shows promise for treating severe COVID19
|
|---|---|
| Published in |
Signal Transduction and Targeted Therapy, November 2020
|
| DOI | 10.1038/s41392-020-00374-6 |
| Pubmed ID | |
| Authors |
Tarek Mohamed Abd El-Aziz, Ahmed Al-Sabi, James D. Stockand |
X Demographics
The data shown below were collected from the profiles of 691 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 145 | 21% |
| United Kingdom | 26 | 4% |
| Turkey | 24 | 3% |
| Canada | 20 | 3% |
| Germany | 14 | 2% |
| India | 13 | 2% |
| Brazil | 8 | 1% |
| Australia | 8 | 1% |
| Spain | 6 | <1% |
| Other | 77 | 11% |
| Unknown | 350 | 51% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 596 | 86% |
| Scientists | 63 | 9% |
| Practitioners (doctors, other healthcare professionals) | 26 | 4% |
| Science communicators (journalists, bloggers, editors) | 6 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 145 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 12% |
| Researcher | 16 | 11% |
| Student > Master | 16 | 11% |
| Student > Doctoral Student | 9 | 6% |
| Other | 8 | 6% |
| Other | 20 | 14% |
| Unknown | 58 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 27 | 19% |
| Medicine and Dentistry | 20 | 14% |
| Agricultural and Biological Sciences | 6 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 4% |
| Immunology and Microbiology | 4 | 3% |
| Other | 21 | 14% |
| Unknown | 61 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 547. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2022.
All research outputs
#45,444
of 25,793,330 outputs
Outputs from Signal Transduction and Targeted Therapy
#12
of 1,569 outputs
Outputs of similar age
#1,516
of 442,665 outputs
Outputs of similar age from Signal Transduction and Targeted Therapy
#1
of 88 outputs
Altmetric has tracked 25,793,330 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,569 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 27.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 442,665 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.